Novartis AG (NYSE:NVS) Holdings Increased by Integral Health Asset Management LLC

Integral Health Asset Management LLC grew its position in Novartis AG (NYSE:NVS - Free Report) by 33.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 300,000 shares of the company's stock after purchasing an additional 75,000 shares during the quarter. Novartis comprises approximately 3.0% of Integral Health Asset Management LLC's investment portfolio, making the stock its 8th biggest position. Integral Health Asset Management LLC's holdings in Novartis were worth $31,938,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the business. EverSource Wealth Advisors LLC raised its position in Novartis by 31.5% in the second quarter. EverSource Wealth Advisors LLC now owns 2,647 shares of the company's stock valued at $295,000 after purchasing an additional 634 shares during the last quarter. Fairscale Capital LLC acquired a new stake in Novartis during the 2nd quarter worth about $171,000. Goepper Burkhardt LLC bought a new position in shares of Novartis in the 2nd quarter worth about $208,000. Frank Rimerman Advisors LLC bought a new stake in shares of Novartis during the 2nd quarter valued at about $242,000. Finally, Holderness Investments Co. increased its holdings in Novartis by 7.4% in the second quarter. Holderness Investments Co. now owns 9,828 shares of the company's stock worth $1,046,000 after purchasing an additional 673 shares in the last quarter. Institutional investors own 13.12% of the company's stock.

Wall Street Analyst Weigh In

NVS has been the subject of several analyst reports. The Goldman Sachs Group reiterated a "neutral" rating and issued a $121.00 target price (up previously from $119.00) on shares of Novartis in a report on Thursday, September 5th. Barclays raised Novartis to a "strong sell" rating in a research report on Monday, June 24th. Bank of America cut shares of Novartis from a "buy" rating to a "neutral" rating and dropped their target price for the company from $135.00 to $130.00 in a research note on Wednesday, September 11th. Jefferies Financial Group lowered shares of Novartis from a "buy" rating to a "hold" rating in a research note on Tuesday, September 3rd. Finally, Deutsche Bank Aktiengesellschaft reissued a "hold" rating on shares of Novartis in a report on Friday, July 19th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $120.70.

Novartis Trading Up 0.5 %

Shares of NYSE:NVS traded up $0.57 during trading on Monday, reaching $116.51. 529,663 shares of the company traded hands, compared to its average volume of 1,386,834. The business's fifty day moving average is $114.22 and its 200-day moving average is $105.50. Novartis AG has a 52-week low of $92.19 and a 52-week high of $120.92. The company has a current ratio of 0.93, a quick ratio of 0.72 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $238.15 billion, a price-to-earnings ratio of 15.65, a P/E/G ratio of 1.75 and a beta of 0.57.

Novartis (NYSE:NVS - Get Free Report) last issued its quarterly earnings data on Thursday, July 18th. The company reported $1.97 earnings per share for the quarter, topping analysts' consensus estimates of $1.87 by $0.10. The firm had revenue of $12.87 billion for the quarter, compared to analyst estimates of $12.24 billion. Novartis had a return on equity of 34.56% and a net margin of 33.76%. During the same period last year, the company earned $1.83 EPS. As a group, analysts forecast that Novartis AG will post 7.5 EPS for the current year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.